Copyright
©The Author(s) 2023.
World J Clin Cases. Aug 26, 2023; 11(24): 5643-5652
Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5643
Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5643
Prognostic factor | HR (95%CI) | P value |
ISS stage | 1.879 (1.315-2.686) | 0.001 |
Age | 1.054 (1.027-1.081) | 0.024 |
DS stage | 1.829 (0.791-4.233) | 0.158 |
GOT | 1.009 (0.988-1.031) | 0.395 |
LDH | 0.998 (0.996-1.001) | 0.264 |
Platelet count | 2.929 (1.269-6.756) | 0.012 |
Autotransplantation | 0.211 (0.069-0.647) | 0.006 |
TC | 0.735 (0.573-0.943) | 0.016 |
C1 reduction rate | 0.868 (0.543-1.387) | 0.553 |
C2 reduction rate | 0.680 (0.386-1.197) | 0.181 |
C3 reduction rate | 1.055 (0.592-1.879) | 0.856 |
C4 reduction rate | 0.608 (0.350-1.058) |
- Citation: Liu M, Zhang JY. Reduction rate of monoclonal protein as a useful prognostic factor in standard-risk group of newly diagnosed multiple myeloma. World J Clin Cases 2023; 11(24): 5643-5652
- URL: https://www.wjgnet.com/2307-8960/full/v11/i24/5643.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i24.5643